# 2025年12月29日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 解码表观遗传与转录图谱：DNA 甲基组—转录组整合揭示 4NQO 诱导食管鳞状细胞癌小鼠模型中的新型驱动因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41456005)
**期刊：** Clinical epigenetics
**PMID：** 41456005
**DOI：** 10.1186/s13148-025-02035-3

### 第一部分 原文与翻译

**英文原标题：** Decoding epigenetic and transcriptional landscapes: DNA methylome-transcriptome integration reveals novel drivers in 4NQO-Induced esophageal squamous cell carcinoma mouse model.

> **英文摘要：**
> BACKGROUND: Epigenetic alterations, particularly DNA methylation, and dysregulation of the tumor immune microenvironment (TIME) are increasingly recognized as critical factors in esophageal squamous cell carcinoma (ESCC) pathogenesis. Understanding the dynamic interplay between DNA methylation changes and TIME evolution during ESCC progression remains essential. We established a 4-nitroquinoline 1-oxide (4NQO)-induced ESCC mouse model, capturing distinct pathological stages: normal esophageal epithelium (Normal), esophageal simple hyperplasia (ESSH), intraepithelial neoplasia (IEN), and ESCC. Genome-wide DNA methylation profiling was performed using the Infinium Mouse Methylation BeadChip (285 K), coupled with transcriptome analysis via bulk RNA sequencing (RNA-seq). Immunohistochemistry (IHC) for Cd45 (leukocyte common antigen) validated immune cell infiltration.
> 
> RESULTS: DNA methylation profiling revealed progressive genome-wide hypomethylation during ESCC development, with hypomethylated probes significantly enriched in immune response pathways. Notably, ESSH exhibited a methylation profile similar to IEN and ESCC. RNA-seq identified escalating numbers of differentially expressed genes (DEGs). Immune deconvolution analysis and IHC of Cd45 demonstrated dynamic changes in TIME composition from ESSH onwards. Furthermore, dynamic expression clustering identified an innate immune response-related gene cluster highly expressed in ESSH. Integrative analysis yielded 495 methylated regulatory genes, significantly enriched in leukocyte cell-cell adhesion and T cell activation pathways (e.g., Ptprc/Cd45, Il12rb1, Tox), with peak activity in ESSH.
> 
> CONCLUSIONS: These findings highlight ESSH as a critical window where epigenetically driven immune changes facilitate ESCC progression. Targeting these early epigenetic-immune interactions may offer a novel strategy for ESCC early detection and combination therapy.

> **中文摘要：**
> 背景：表观遗传改变，特别是 DNA 甲基化异常，以及肿瘤免疫微环境（TIME）的失调，正日益被认为是食管鳞状细胞癌（ESCC）发病的重要因素。理解 ESCC 进展过程中 DNA 甲基化变化与 TIME 演化之间的动态相互作用至关重要。本研究建立了 4-硝基喹啉-1-氧化物（4NQO）诱导的 ESCC 小鼠模型，涵盖不同病理阶段：正常食管上皮（Normal）、食管单纯性增生（ESSH）、上皮内瘤变（IEN）及 ESCC。利用 Infinium Mouse Methylation BeadChip（285K）进行了全基因组 DNA 甲基化分析，并结合整体 RNA 测序（RNA-seq）进行转录组分析。通过针对 Cd45（白细胞共同抗原）的免疫组化（IHC）验证了免疫细胞浸润。
> 
> 结果：DNA 甲基化分析显示，在 ESCC 发生发展过程中，基因组范围内的甲基化水平逐渐降低，且低甲基化探针显著富集于免疫应答相关通路。值得注意的是，ESSH 的甲基化谱与 IEN 和 ESCC 相似。RNA-seq 显示差异表达基因（DEGs）数量逐步增加。免疫反卷积分析与 Cd45 的 IHC 结果揭示，自 ESSH 阶段起 TIME 组成发生动态变化。此外，动态表达聚类分析鉴定出一个与先天免疫反应相关的基因簇在 ESSH 阶段高表达。整合分析共获得 495 个甲基化调控基因，它们显著富集于白细胞细胞间黏附和 T 细胞活化通路（如 Ptprc/Cd45、Il12rb1、Tox），且在 ESSH 阶段达到活性峰值。
> 
> 结论：研究结果强调 ESSH 是表观遗传驱动免疫变化促进 ESCC 进展的关键窗口。针对这些早期的表观遗传—免疫相互作用，可能为 ESCC 的早期检测与联合治疗提供新的策略。

### 第二部分 AI 大师评价

本研究通过结合 DNA 甲基组与转录组分析，系统揭示了 4NQO 诱导的食管鳞状细胞癌小鼠模型中表观遗传改变与免疫微环境重塑的动态关联。结果表明，在食管单纯性增生阶段已出现显著的免疫相关表观遗传调控，为癌变奠定基础。研究突出指出 ESSH 阶段是 ESCC 免疫表观变化的关键窗口，具有潜在的早期干预意义。该研究的创新点在于多组学整合视角下发现免疫驱动的早期表观遗传标志物，局限性在于动物模型与临床转化之间仍需进一步验证。

---

## 2. NAT10通过促进PPAN调控的DNA损伤修复驱动结直肠癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455833)
**期刊：** Oncogene
**PMID：** 41455833
**DOI：** 10.1038/s41388-025-03661-0

### 第一部分 原文与翻译

**英文原标题：** NAT10 triggers colorectal cancer progression via promoting PPAN-regulated DNA damage repair.

> **英文摘要：**
> RNA modification recognition proteins are crucial in cancer development and progression. Among all RNA modification-related proteins (RMRPs), Weighted Gene Co-expression Network Analysis (WGCNA), combined with comprehensive bioinformatic analysis, suggests that NAT10-the sole known writer of N4-acetylcytidine (ac4C)-is a critical regulatory protein in colorectal cancer (CRC) progression. NAT10 facilitates the malignancy phenotypes and DNA damage repair in CRC cells via its ac4C transferase activity and regulation of PPAN. Specifically, NAT10 enhances the translation efficiency of PPAN via acetylation at the C744 and C747 sites. In addition, NAT10 promotes the translation of ac4C-modified MYC mRNA. MYC protein then enhances PPAN transcription through binding to the PPAN promoter. The newly identified ac4C reader protein MYBBP1A mediates NAT10-induced translation of both PPAN and MYC. We further found that VDR binds to the NAT10 promoter to activate its transcription, resulting in the high expression of NAT10 in CRC. Xenograft studies and clinical data confirmed the role of the NAT10-PPAN axis in promoting CRC development and DNA damage repair. Collectively, our study reveals the role and underlying mechanism of mRNA ac4C modification in CRC progression, providing critical potential targets for CRC drug development.

> **中文摘要：**
> RNA修饰识别蛋白在癌症的发生与进展中具有关键作用。在所有RNA修饰相关蛋白（RMRPs）中，基于加权基因共表达网络分析（WGCNA）结合综合生物信息学分析的结果显示，NAT10——已知唯一的N4-乙酰胞苷（ac4C）写入酶——是结直肠癌（CRC）进展中的关键调控蛋白。NAT10通过其ac4C转移酶活性及对PPAN的调控，促进了CRC细胞的恶性表型及DNA损伤修复。具体而言，NAT10通过在C744和C747位点的乙酰化增强了PPAN的翻译效率。此外，NAT10促进了ac4C修饰的MYC mRNA的翻译。随后，MYC蛋白通过结合PPAN启动子增强PPAN的转录。新鉴定的ac4C读取蛋白MYBBP1A介导了NAT10诱导的PPAN和MYC的翻译。我们进一步发现，VDR通过结合NAT10启动子激活其转录，从而导致CRC中NAT10的高表达。异种移植实验和临床数据证实了NAT10-PPAN轴在促进CRC发展与DNA损伤修复中的作用。总体而言，本研究揭示了mRNA ac4C修饰在CRC进展中的作用及其潜在机制，为CRC药物开发提供了重要的潜在靶点。

### 第二部分 AI 大师评价

本研究聚焦于RNA修饰领域，系统解析了NAT10在结直肠癌进展中的关键作用及其分子机制。作者通过多组学分析及实验验证，揭示了NAT10通过ac4C修饰促进PPAN和MYC表达，从而增强DNA损伤修复与肿瘤细胞恶性表型。研究发现VDR介导的NAT10转录激活进一步解释其高表达来源，构建了VDR–NAT10–PPAN–MYC调控轴。该研究在RNA修饰与肿瘤信号交叉机制上具有创新性，但仍需在临床样本及药物靶向可行性方面进一步验证。

---

## 3. 可溶性环氧化物水解酶的磷酸酶活性通过焦磷酸阴离子代谢调控血管钙化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455787)
**期刊：** Cell death & disease
**PMID：** 41455787
**DOI：** 10.1038/s41419-025-08390-6

### 第一部分 原文与翻译

**英文原标题：** The phosphatase activity of soluble epoxide hydrolase regulates vascular calcification through the metabolism of pyrophosphate anions.

> **英文摘要：**
> While the hydrolase activity of soluble epoxide hydrolase (sEH) reduces vascular calcification, it is not known whether the phosphatase activity of sEH (sEH-P) is also involved. Pharmacological and genetic inhibition of sEH-P reduced the increased calcium deposition in rat aortic rings cultured under high-phosphate conditions. This was associated with decreased mRNA expression of the osteochondrogenic markers Msx2 and Sox9. Deendothelialization of the aortic rings abolished this anticalcifying effect, while the calcification of human aortic smooth muscle cells was unaffected by sEH-P inhibition, suggesting a predominant role of the endothelium. Endothelial NO release did not appear to contribute, but an increased level of the calcification inhibitor pyrophosphate anions (PPi) was observed in the culture supernatant of aortic rings when sEH-P was inhibited. In vitro experiments demonstrated that PPi is a substrate of sEH-P, and that inhibiting sEH-P prevented the high-phosphate induced decrease of PPi in human aortic endothelial cells. Furthermore, the aortic calcification related to chronic kidney disease induced by subtotal nephrectomy was reduced in sEH-P-deficient rats compared to wild-type rats. This was associated with an improvement in flow-induced isolated mesenteric artery dilatation and a reduction of cardiac hypertrophy and fibrosis. Vascular calcification is regulated by sEH-P through the metabolism of endothelial PPi. The prevention of vascular calcification, together with the reduction in vascular dysfunction and cardiac remodeling, suggests that inhibiting sEH-P may help to prevent the cardiovascular complications associated with chronic kidney disease.

> **中文摘要：**
> 虽然可溶性环氧化物水解酶（sEH）的水解酶活性可减少血管钙化，但尚不清楚其磷酸酶活性（sEH-P）是否也参与其中。药理学和遗传学抑制sEH-P可减轻高磷条件下培养的大鼠主动脉环中的钙沉积增加。这一变化伴随着成骨软骨分化标志物Msx2和Sox9的mRNA表达下降。去除主动脉环内皮后，这种抗钙化作用消失，而抑制sEH-P对人主动脉平滑肌细胞钙化无影响，提示内皮细胞可能起主要作用。内皮一氧化氮释放似乎未参与其中，但在抑制sEH-P时，主动脉环培养上清液中钙化抑制因子焦磷酸阴离子（PPi）水平升高。体外实验表明PPi是sEH-P的底物，且在抑制sEH-P时可防止人主动脉内皮细胞中由高磷诱导的PPi下降。此外，与野生型大鼠相比，在亚全肾切除诱导的慢性肾病模型中，缺失sEH-P的大鼠表现出主动脉钙化减少。这伴随着流动诱导的肠系膜动脉扩张改善以及心脏肥厚和纤维化的减轻。sEH-P通过调节内皮PPi代谢来控制血管钙化。血管钙化的预防以及血管功能障碍和心脏重构的减少，提示抑制sEH-P可能有助于预防慢性肾病相关的心血管并发症。

### 第二部分 AI 大师评价

本研究揭示了可溶性环氧化物水解酶磷酸酶活性在血管钙化调控中的关键作用。作者通过药理学与基因学手段证实，抑制sEH-P能减轻高磷诱导的钙化，并通过增加内皮来源的焦磷酸盐水平实现该效应。动物实验进一步显示，sEH-P缺失可改善与慢性肾病相关的血管钙化、心脏肥厚及血管功能障碍。研究创新性地指出sEH-P是PPi代谢的重要调控节点，为慢性肾病心血管并发症提供了新的潜在干预靶点。未来仍需在临床和机制层面探讨其安全性与普适性。

---

## 4. 群体结构可逆转具有比例性出生与死亡率变异体的选择效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455764)
**期刊：** Nature communications
**PMID：** 41455764
**DOI：** 10.1038/s41467-025-66951-x

### 第一部分 原文与翻译

**英文原标题：** Population structure reverses selection of variants with proportionally scaled birth and death rates.

> **英文摘要：**
> A widespread biological phenomenon is that higher reproduction rates are often accompanied by higher mortality. During tumor progression, variants can both reproduce and die faster; rapidly replicating viruses decay more quickly; arthropods with faster reproduction have shorter lifespans; and in ecological systems, more frequent reproduction can increase predation risk. Variants with proportionally scaled birth and death rates are termed quasi-neutral mutants. Although their lifetime reproductive success is unchanged, such mutants have fixation probabilities slightly lower (or higher) than neutral mutants if birth and death rates are proportionally larger (or smaller). Previous studies, limited to well-mixed populations, showed that quasi-neutral mutants deviate from neutrality but still exhibit fixation probabilities scaling with their initial frequencies. Here, we show that in deme- or spatially structured populations, variants with proportionally increased (decreased) birth and death rates become genuinely disadvantageous (advantageous). We calculate their effective fitness and further demonstrate that even when mutants have higher lifetime reproductive output, proportional increases in both birth and death rates can render them strongly disadvantageous-and vice versa. This effect intensifies in larger populations. These findings revise the relationship between lifetime reproductive success and selection, with implications for evolutionary dynamics across biological systems.

> **中文摘要：**
> 一种普遍存在的生物学现象是，更高的繁殖率常常伴随着更高的死亡率。在肿瘤进展过程中，变异体可以同时更快地繁殖和死亡；快速复制的病毒衰减得更快；繁殖更快的节肢动物寿命更短；而在生态系统中，更频繁的繁殖会增加被捕食的风险。具有按比例缩放的出生率和死亡率的变体被称为准中性突变体。尽管它们的终生繁殖成功率不变，但当出生率和死亡率按比例增大（或减小）时，这类突变体的固定概率略低（或略高）于中性突变体。先前仅限于充分混合群体的研究表明，准中性突变体虽偏离中性，但其固定概率仍随其初始频率而变化。在此，我们展示，当种群具有亚群或空间结构时，出生和死亡率按比例增加（或减少）的变异体会分别变得真正不利（或有利）。我们计算了它们的有效适合度，并进一步证明，即使突变体具有较高的终生繁殖产出，同时按比例提高出生率和死亡率也可能使其显著处于不利地位——反之亦然。该效应在较大的种群中更为显著。这些发现修正了终生繁殖成功率与自然选择之间的关系，对各种生物系统的进化动力学具有重要启示。

### 第二部分 AI 大师评价

该研究旨在揭示当出生率与死亡率按比例变化时，群体结构如何影响变异体的选择效应。作者通过理论推导和模型分析，发现空间或亚群结构能够逆转准中性突变体的选择方向，使得原本在充分混合群体中近似中性的变异表现出优势或劣势。研究进一步表明，尽管突变体的终生繁殖产量更高，但比例性地提高出生与死亡率可能导致适合度损失，其效应在大种群中更为突出。该工作创新性地修正了关于繁殖成功与选择关系的经典理解，为不同生物系统的进化规律提供了新的理论框架。

---

## 5. KIRA6抑制髓源性抑制性细胞的生成并克服抗PD-1治疗耐受性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455743)
**期刊：** Cell death & disease
**PMID：** 41455743
**DOI：** 10.1038/s41419-025-08401-6

### 第一部分 原文与翻译

**英文原标题：** KIRA6 restrains the generation of myeloid-derived suppressor cells and overcomes resistance to anti-PD-1 therapy.

> **英文摘要：**
> Immune checkpoint blockade (ICB) therapy is one of the cornerstones of cancer treatment regimens, but the overall response rates remain low because of suppressive immune cells, such as myeloid-derived suppressor cells (MDSC). Therefore, it is unmet need to target MDSC to achieve better outcomes of ICB therapy. Inositol-requiring enzyme 1α (IRE1α) is identified as a key regulator for the generation of MDSC. Here, we evaluated the potential of KIRA6, an inhibitor for IREα kinase activity and RNase activity, to abrogate MDSC-mediated immune suppression. KIRA6 significantly suppressed 4T1 tumor growth, decreased MDSC population and enhanced T cell infiltration. Two dosages of KIRA6 treatment directly inhibited extramedullary myelopoiesis and MDSC generation in vivo. KIRA6 abrogated the induction of MDSC from bone marrow cells and abolished the immunosuppressive capability of MDSC in vitro. Meanwhile, KIRA6 not only attenuated G-CSF production from tumor cells thereby blocking the induction of MDSC, but also caused apoptosis of tumor cells. Moreover, KIRA6 treatment diminished MDSC generation, restored T cell proportion in both local and systemic immune landscapes and eventually overcame resistance to anti-PD-1 therapy. Our work establishes the evidence for KIRA6 as an impressive agent for abrogating MDSC-mediated immune suppression, killing tumor, and overcoming ICB resistance.

> **中文摘要：**
> 免疫检查点阻断（ICB）治疗是癌症治疗方案的基石之一，但由于存在抑制性免疫细胞（如髓源性抑制性细胞，MDSC），总体反应率仍然偏低。因此，靶向MDSC以改善ICB治疗效果是一项未满足的需求。肌醇需求酶1α（IRE1α）被确定为调控MDSC生成的关键因子。本研究评估了KIRA6（一种IRE1α激酶活性和RNase活性抑制剂）在消除MDSC介导的免疫抑制中的潜力。KIRA6显著抑制了4T1肿瘤生长，降低了MDSC数量并增强了T细胞浸润。两种剂量的KIRA6处理在体内直接抑制了髓外造血和MDSC生成。KIRA6阻止了来自骨髓细胞的MDSC诱导，并在体外消除了MDSC的免疫抑制能力。同时，KIRA6不仅减弱了肿瘤细胞来源的粒细胞集落刺激因子（G-CSF）产生，从而阻断了MDSC的诱导，还诱导了肿瘤细胞的凋亡。此外，KIRA6治疗减少了MDSC生成，恢复了局部及全身免疫环境中的T细胞比例，并最终克服了抗PD-1治疗的耐受性。本研究提供了证据，表明KIRA6是一种能够有效消除MDSC介导免疫抑制、杀伤肿瘤并克服ICB耐药的有潜力药物。

### 第二部分 AI 大师评价

该研究旨在探索IRE1α抑制剂KIRA6在解除MDSC介导的免疫抑制及改善抗PD-1疗效中的作用。作者通过体内外模型发现，KIRA6不仅能抑制MDSC生成和功能，还能促进T细胞浸润并诱导肿瘤细胞凋亡，从而有效克服抗PD-1耐药。研究揭示了IRE1α信号与免疫抑制之间的新关联，提供了ICB联合治疗的新策略。其创新性在于将IRE1α通路与MDSC生成直接联系，而局限性在于仍需更多临床前验证和安全性评估。

---

## 6. 中国不同年龄组中基于HPV与基于细胞学的宫颈癌筛查临床表现比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455735)
**期刊：** Nature communications
**PMID：** 41455735
**DOI：** 10.1038/s41467-025-67215-4

### 第一部分 原文与翻译

**英文原标题：** Age-specific clinical performance of HPV-based vs. cytology-based cervical cancer screening in China.

> **英文摘要：**
> Cervical cancer remains a significant health burden, and effective screening is essential, yet the age-specific performance of HPV primary screening is rarely studied. This multicenter study evaluates age-specific performance of primary human papillomavirus (HPV) testing as cross-sectional and longitudinal screening for cervical cancer among 28,501 Chinese women. At baseline, HPV screening with cytology triage demonstrates higher sensitivity (96.9% vs. 79.7%) but slightly lower specificity (88.8% vs. 92.7%) than cytology with HPV triage for cervical intraepithelial neoplasia grade 2 or worse (CIN2+). HPV sensitivities remain high across age groups (≤35: 100.0%; 36-45: 96.4%; >45: 96.8%), consistently exceeding the corresponding cytology sensitivities (66.7%, 75.7%, and 84.9%). Over a three-year follow-up, HPV screening maintains superior sensitivity (93.1% vs. 58.1%) and slightly lower specificity (89.6% vs. 92.4%) compared with cytology. Age-stratified analyses in the longitudinal setting reveal trends similar to those observed in the cross-sectional analyses. Women positive for HPV16/18 have a 43.0% three-year risk of CIN2+, compared with 0.2% for HPV-negative women. These findings support the durable protection of HPV-based screening and the feasibility of extending screening intervals.

> **中文摘要：**
> 宫颈癌仍然是一个重大的健康负担，而有效的筛查至关重要，然而关于HPV初筛在不同年龄群体中的表现研究较少。本项多中心研究评估了动态和横断面筛查中针对28,501名中国女性的HPV初筛在不同年龄层的表现。在基线时，采用细胞学分流的HPV筛查对宫颈上皮内瘤变2级或更高级别病变（CIN2+）的敏感性更高（96.9% vs. 79.7%），但特异性略低（88.8% vs. 92.7%），与采用HPV分流的细胞学筛查相比。在各年龄组中，HPV筛查的敏感性均保持较高（≤35岁：100.0%；36–45岁：96.4%；>45岁：96.8%），始终高于相应的细胞学敏感性（66.7%、75.7% 和 84.9%）。在三年随访中，HPV筛查在敏感性上仍具优势（93.1% vs. 58.1%），而特异性略低（89.6% vs. 92.4%），与细胞学相比差异相似。纵向分层分析显示出与横断面分析一致的趋势。HPV16/18阳性的女性三年内发生CIN2+的风险为43.0%，而HPV阴性女性仅为0.2%。这些结果支持基于HPV的筛查在长期保护方面的可靠性，并显示延长筛查间隔的可行性。

### 第二部分 AI 大师评价

本研究针对中国女性不同年龄层比较了HPV检测筛查与传统细胞学筛查在宫颈癌预防中的临床表现。研究采用多中心设计，结合横断面与纵向数据，揭示HPV检测具有更高的敏感性但稍低的特异性。在三年随访中，其敏感性优势持续，并显示不同年龄组间差异较小。结果强化了HPV筛查在持续防护与延长筛查间隔方面的潜力。然而，特异性下降及长期经济性仍需进一步研究验证。

---

## 7. ENO1通过稳定RRM2介导脱氧胞苷合成并促进胰腺癌对吉西他滨的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455715)
**期刊：** Cell death & disease
**PMID：** 41455715
**DOI：** 10.1038/s41419-025-08061-6

### 第一部分 原文与翻译

**英文原标题：** ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma is a highly malignant solid tumor of the digestive tract, and chemoresistance to gemcitabine is an important cause of shortened survival time in patients. Upregulation of deoxypyrimidine synthesis is one of the important reasons for pancreatic cancer cells to be resistant to gemcitabine, however, the specific mechanism leading to increased deoxypyrimidine synthesis in pancreatic cancer cells is still unclear. Ribonucleotide reductase M2 subunit (RRM2) is overexpressed through unclear mechanisms in many types of human cancer significantly affects sensitivity to various chemotherapy treatments. Here, we found that high expression of enolase-1 (ENO1) is closely related to gemcitabine resistance in pancreatic cancer patients. Cellular experiments and in vivo experiments confirmed that ENO1 increases the resistance of pancreatic cancer to gemcitabine without relying on its glycolytic enzyme activity. Mechanistically, ENO1 competitively binds to RRM2 with ubiquitin E3 ligase STUB1, thereby weakening the ubiquitination and degradation of RRM2 by STUB1. This ENO1-mediated aggregation of RRM2 protein increases the synthesis of dNTPs in pancreatic cancer cells, enhancing the resistance of pancreatic cancer to gemcitabine. Our study reveals a role of ENO1 in pancreatic cancer via RRM2-STUB1 axis and provides a scientific basis for the development of new therapeutic strategies targeting ENO1.

> **中文摘要：**
> 胰腺导管腺癌是一种消化道中高度恶性的实体瘤，对吉西他滨的化疗耐药是导致患者生存时间缩短的重要原因。脱氧嘧啶合成的上调是胰腺癌细胞对吉西他滨产生耐药的主要原因之一，然而导致胰腺癌细胞中脱氧嘧啶合成增加的具体机制尚不清楚。核苷酸还原酶M2亚基(RRM2)在多种人类癌症中通过不明机制高表达，显著影响对多种化疗药物的敏感性。在本研究中，我们发现烯醇化酶1(ENO1)的高表达与胰腺癌患者对吉西他滨的耐药密切相关。细胞实验和体内实验均证实，ENO1可在不依赖其糖酵解酶活性的情况下增加胰腺癌对吉西他滨的耐药性。在机制上，ENO1与泛素E3连接酶STUB1竞争性结合RRM2，从而削弱STUB1对RRM2的泛素化和降解。该ENO1介导的RRM2蛋白积累增加了胰腺癌细胞中dNTP的合成，从而增强其对吉西他滨的耐药性。本研究揭示了ENO1通过RRM2-STUB1轴在胰腺癌中的作用，并为开发靶向ENO1的新型治疗策略提供了科学依据。

### 第二部分 AI 大师评价

该研究聚焦胰腺癌吉西他滨耐药机制，发现ENO1可通过与RRM2及STUB1的竞争性相互作用稳定RRM2蛋白，从而促进dNTP合成并增强肿瘤耐药。研究采用体内外实验验证了ENO1的非糖酵解功能在耐药形成中的关键作用，阐明了RRM2-STUB1调控轴的新机制。该工作为开发针对ENO1的抗耐药靶向药物提供了潜在方向，但仍需在临床样本与动物模型中进一步验证其治疗可行性。

---

## 8. ALFA-K：核型适应度景观的局部自适应映射

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455703)
**期刊：** Nature communications
**PMID：** 41455703
**DOI：** 10.1038/s41467-025-67750-0

### 第一部分 原文与翻译

**英文原标题：** ALFA-K: Local adaptive mapping of karyotype fitness landscapes.

> **英文摘要：**
> Despite its critical role in tumor evolution, a detailed quantitative understanding of the evolutionary dynamics of aneuploidy remains elusive. Here we introduce ALFA-K (Adaptive Local Fitness landscapes for Aneuploid Karyotypes), a method that infers chromosome-level karyotype fitness landscapes from longitudinal single-cell data. ALFA-K estimates fitness of thousands of karyotypes closely related to observed populations, enabling robust prediction of emergent karyotypes not yet experimentally detected. We validate ALFA-K's performance using synthetic data from an agent-based model and empirical data from in vitro and in vivo passaged cell lines. Analysis of fitted landscapes suggests several key insights: (1) Whole genome doubling facilitates aneuploidy evolution by narrowing the spectrum of deleterious copy-number changes; (2) Environmental context and cisplatin treatment significantly modulate the fitness impact of these changes; (3) Fitness effects of copy-number changes depend on parental karyotype; and (4) Chromosome mis-segregation rates strongly influence the predominant karyotypes in evolving populations.

> **中文摘要：**
> 尽管非整倍体在肿瘤演化中发挥关键作用，但对其进化动力学的定量化细节理解仍不充分。本文介绍了ALFA-K（Adaptive Local Fitness landscapes for Aneuploid Karyotypes，即非整倍体核型的自适应局部适应度景观）方法，该方法可基于纵向单细胞数据推断染色体水平的核型适应度景观。ALFA-K评估与观测人群密切相关的数千种核型的适应度，从而能够稳健地预测尚未在实验中检测到的新兴核型。我们利用基于代理的模型合成数据以及体外与体内传代细胞系的实证数据，对ALFA-K的性能进行了验证。对拟合景观的分析揭示了若干关键见解：（1）全基因组加倍通过缩小有害拷贝数改变的谱系范围促进了非整倍体进化；（2）环境背景及顺铂处理显著调节这些改变的适应度效应；（3）拷贝数改变的适应度影响取决于母核型；（4）染色体错误分离率强烈影响进化群体中占主导地位的核型。

### 第二部分 AI 大师评价

该研究旨在通过ALFA-K算法实现非整倍体核型适应度景观的定量推断，运用纵向单细胞与模型数据揭示染色体层面的演化规律。其创新在于首次实现对多种核型适应度的局部数据驱动估计，并能预测潜在新核型的出现。结果指出全基因组加倍、环境因素和化疗药物对核型适应度进化均具显著影响。该方法在理解肿瘤进化的复杂动态方面提供了新的计算框架，但仍需更多不同生物类型的数据验证其普适性。

---

## 9. 核糖体生物发生作为 KRAS 突变型结直肠癌的潜在治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455700)
**期刊：** Nature communications
**PMID：** 41455700
**DOI：** 10.1038/s41467-025-67979-9

### 第一部分 原文与翻译

**英文原标题：** Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer.

> **英文摘要：**
> Molecular targeted therapies targeting KRAS signaling have significantly improved patient outcomes, but they have not achieved sufficient therapeutic efficacy in colorectal cancer (CRC). Here, we demonstrate that a subset of KRAS-mutant CRC cells transitions to a cellular state characterized by enhanced ribosome biogenesis upon KRAS signaling inhibition. The mitogen-activated protein kinase kinase inhibitor, trametinib, and AMG510 induce a cellular state characterized by a gene expression profile highly enriched for ribosome biogenesis. We find that they are vulnerable to the inhibition of RNA polymerase I, and they exhibit synergistic anti-tumor effects with trametinib in an autochthonous mouse model of intestinal tumors and human patient-derived organoids (PDOs). These observations demonstrate that high ribosome biogenesis induced by KRAS inhibition is indispensable to maintain this cellular state and is a potential therapeutic target. Overall, this study reveals novel mechanisms of drug tolerance to KRAS inhibition, thereby facilitating the development of new therapeutic strategies.

> **中文摘要：**
> 针对 KRAS 信号通路的分子靶向治疗已显著改善患者预后，但在结直肠癌（CRC）中尚未取得足够的治疗效果。我们在此表明，一部分 KRAS 突变型结直肠癌细胞在 KRAS 信号受抑制后，会转变为一种以增强的核糖体生物发生为特征的细胞状态。丝裂原活化蛋白激酶激酶抑制剂 trametinib 和 AMG510 可诱导一种在基因表达谱上高度富集核糖体生物发生相关基因的细胞状态。我们发现，这些细胞对 RNA 聚合酶 I 的抑制高度敏感，并在肠道肿瘤自发性小鼠模型及来源于人类患者的类器官（PDOs）中与 trametinib 呈现协同抗肿瘤作用。这些观察结果说明，KRAS 抑制诱导的高核糖体生物发生对于维持该细胞状态是不可或缺的，并构成潜在的治疗靶点。总体而言，本研究揭示了 KRAS 抑制耐药的新机制，从而有助于开发新的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明 KRAS 抑制后结直肠癌细胞的适应性反应及潜在治疗靶点。作者利用药物处理实验、小鼠自发性肠道肿瘤模型及患者来源类器官，发现 KRAS 突变细胞在信号被阻断后会激活核糖体生物发生相关程序，并对 RNA 聚合酶 I 抑制表现出敏感性。进一步研究表明，联合使用 trametinib 与 RNA 聚合酶 I 抑制剂可产生协同抗肿瘤效应。该工作为克服 KRAS 靶向治疗耐受性提供了新思路，但其机制的临床可转化性仍需进一步验证。

---

## 10. 一种针对实体瘤的CAR-T治疗新策略：IL-15自分泌信号增强肿瘤基质清除并促进肿瘤微环境中的T细胞亚群。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455698)
**期刊：** Cell death & disease
**PMID：** 41455698
**DOI：** 10.1038/s41419-025-08405-2

### 第一部分 原文与翻译

**英文原标题：** A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a T subset in the TME.

> **英文摘要：**
> Although chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable therapeutic effects in treating hematologic cancers, its effectiveness in solid tumors remains significantly restricted. the primary reason is the immunosuppression mediated by the tumor microenvironment (TME), which leads to rapid exhaustion of infiltrating CAR-T cells. To enhance CAR-T cell efficacy against solid tumors, we pursued improvements in two aspects. First, we constructed fibroblast activation protein (FAP)-directed CAR-T cells to enhance their anti-CAF capability within the TME, thereby alleviating the immunosuppressive barrier. Second, we utilized IL-15, an efficient activator of CAR-T cells that inhibits activation-induced cell death, restores effector functions, and increases the proportion of the T stem cell memory (T) subpopulation. In this study, we report the generation of FAP/IL-15 CAR-T cells, which target FAP and autonomously synthesize and secrete IL-15. Our data demonstrate that treatment with FAP/IL-15 CAR-T cells exhibited stronger activation characteristics in a FAP antigen-dependent manner, selectively targeting CAFs within the solid TME. Moreover, endogenous IL-15 secretion enabled CAR-T cells to adopt a T-like phenotype with enhanced memory characteristics, thus improving cell survival, proliferation, activation, and therapeutic efficacy against solid tumors.

> **中文摘要：**
> 尽管嵌合抗原受体（CAR）T细胞治疗在血液系统肿瘤治疗中取得了显著疗效，但其在实体瘤中的效果仍受到显著限制。其主要原因是肿瘤微环境（TME）介导的免疫抑制，导致浸润的CAR-T细胞快速耗竭。为提高CAR-T细胞对实体瘤的治疗效能，我们从两个方面进行了改进。首先，我们构建了针对成纤维细胞激活蛋白（FAP）的CAR-T细胞，以增强其在TME中对癌相关成纤维细胞（CAF）的清除能力，从而缓解免疫抑制屏障。其次，我们利用IL-15，这是一种高效的CAR-T细胞激活因子，可抑制激活诱导的细胞死亡，恢复效应功能，并增加T记忆干细胞（T）亚群的比例。在本研究中，我们报道了FAP/IL-15 CAR-T细胞的构建，这些细胞可同时靶向FAP并自主合成和分泌IL-15。我们的数据显示，FAP/IL-15 CAR-T细胞在FAP抗原依赖性作用下具有更强的激活特征，能够选择性地靶向实体瘤TME中的CAF。此外，内源性IL-15的分泌使CAR-T细胞呈现出类似T记忆细胞的表型，具备增强的记忆特征，从而改善了细胞存活、增殖、活化和针对实体瘤的治疗效能。

### 第二部分 AI 大师评价

本研究提出了一种创新的CAR-T细胞策略，通过FAP靶向和IL-15自分泌信号双重改造，以解除肿瘤微环境免疫抑制并增强细胞持久性。研究展示了该FAP/IL-15 CAR-T在实体瘤模型中可实现选择性清除CAF、激活增强及记忆表型维持。该策略在克服CAR-T疗法在实体瘤中的局限方面具有显著创新性，但其长期安全性及体内调控机制仍需进一步验证。整体而言，该研究为未来实体瘤CAR-T治疗的优化提供了新的思路和实验基础。

---

## 11. 伊沙妥昔单抗皮下注射联合卡非佐米和地塞米松在复发/难治性多发性骨髓瘤患者中的疗效与安全性：IZALCO II期研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455697)
**期刊：** Blood cancer journal
**PMID：** 41455697
**DOI：** 10.1038/s41408-025-01436-0

### 第一部分 原文与翻译

**英文原标题：** Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

> **英文摘要：**
> In the Phase 2 IZALCO study, we evaluated efficacy, patient preference, safety and pharmacokinetics for isatuximab administered SC by an innovative on-body injector (OBI) or manual injection, plus carfilzomib-dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) patients. In Part 1, isatuximab SC was injected manually (cycles 1-6). In Part 2, patients were randomized to isatuximab SC by manual injection (cycles 1-3) followed by OBI administration (cycles 4-6) or to isatuximab OBI (cycles 1-3) followed by manual injection (cycles 4-6). From cycle 7, all patients could choose either treatment method. Overall, 74 RRMM patients received isatuximab SC plus Kd: 8 in Part 1 and 66 in Part 2. The patients had a median age of 65.0 years (44-85) with a median of 1 prior treatment line (1-5). The study met its primary efficacy endpoint with a 79.7% overall response rate (N = 74), at a median follow-up of 10.1 months. 74.5% of patients preferred the OBI rather than manual injection, 17% preferred manual injection, 8.5% had no preference. No impact of the SC delivery method was observed on efficacy, safety, pharmacokinetics, and immunogenicity of isatuximab given SC plus Kd, supporting the feasibility of using the OBI as a convenient method for isatuximab SC administration. Clinical trial information: ClinicalTrials.gov NCT05704049.

> **中文摘要：**
> 在IZALCO II期研究中，我们评估了通过创新的体戴式注射装置（OBI）或人工注射皮下注射伊沙妥昔单抗（SC），联合卡非佐米－地塞米松（Kd）在复发/难治性多发性骨髓瘤（RRMM）患者中的疗效、患者偏好、安全性及药代动力学特征。在第1部分中，伊沙妥昔单抗SC采用人工注射方式（第1－6个治疗周期）。在第2部分中，患者被随机分配至两种方案之一：方案A为前3个周期人工注射，后3个周期经OBI给药；方案B为前3个周期OBI给药，后3个周期人工注射。从第7个周期起，所有患者可选择任意一种给药方式。总体上，共有74例RRMM患者接受了伊沙妥昔单抗SC联合Kd治疗：第1部分8例，第2部分66例。患者中位年龄为65.0岁（范围44－85岁），既往治疗线中位数为1线（范围1－5线）。在中位随访10.1个月时，研究达到了其主要疗效终点，总体缓解率为79.7%（N=74）。此外，74.5%的患者更倾向于OBI给药，17%偏好人工注射，8.5%无明显偏好。研究未观察到皮下注射途径对伊沙妥昔单抗联合Kd疗效、安全性、药代动力学或免疫原性的影响，支持采用OBI作为伊沙妥昔单抗皮下注射的便利可行方案。临床试验注册号：ClinicalTrials.gov NCT05704049。

### 第二部分 AI 大师评价

该研究旨在探索伊沙妥昔单抗皮下注射联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤的可行性与安全性。研究设计严谨，比较了创新体戴式注射装置与人工注射的差异，结果显示两种方式在疗效和安全性上相当，而多数患者倾向于OBI模式，彰显其临床便利性。79.7%的总体缓解率体现了良好的治疗反应。研究创新性体现在SC OBI给药方式的验证，但样本量及中位随访时间仍有限，后续需更长时间和更大规模验证。

---

## 12. 细胞器与癌细胞焦亡：概述与前景展望

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455695)
**期刊：** Cell death & disease
**PMID：** 41455695
**DOI：** 10.1038/s41419-025-08371-9

### 第一部分 原文与翻译

**英文原标题：** Organelles and cancer cell pyroptosis: overview and perspectives.

> **英文摘要：**
> Pyroptosis, a gasdermin (GSDM)-mediated immunogenic programmed cell death modality, manifests through characteristic membrane permeabilization and proinflammatory cytokine release. Pyroptosis exhibits dual therapeutic advantages by remodeling the tumor microenvironment and potentiating systemic anti-tumor immunity, positioning it as a pivotal focus in cancer immunotherapy. However, researchers still focus current pyroptosis induction strategies predominantly on single molecular targets and have not sufficiently analyzed the inter-organelle communication networks that govern pyroptotic signaling cascades. This review provides a systematic exploration of organelle-specific ultrastructural alterations during pyroptosis progression and the molecular machinery regulating organelle-mediated pyroptotic pathways. We synthesize recent advances in organelle-targeted pyroptosis induction strategies, elucidating how inter-organelle crosstalk networks to enhance therapeutic efficacy. We aim to provide translational approaches for optimizing cancer treatment paradigms.

> **中文摘要：**
> 焦亡是一种由gasdermin（GSDM）介导的免疫原性程序性细胞死亡方式，其特征为细胞膜通透性增加和促炎细胞因子的释放。焦亡通过重塑肿瘤微环境并增强系统性抗肿瘤免疫而展现出双重治疗优势，使其成为癌症免疫治疗的关键研究焦点。然而，目前研究者们的焦亡诱导策略仍主要集中于单一分子靶点，尚未充分分析调控焦亡信号级联反应的细胞器间通信网络。本综述系统探讨了焦亡进程中细胞器特异性的超微结构改变及调控细胞器介导焦亡通路的分子机制。我们综合了近年来细胞器靶向焦亡诱导策略的最新进展，阐明了细胞器间串话如何协同提升治疗效果。研究旨在为优化癌症治疗范式提供可转化的研究思路。

### 第二部分 AI 大师评价

该综述文章以焦亡与细胞器相互作用为核心，系统梳理了焦亡过程中细胞器结构变化及其分子调控机制。作者指出当前研究多集中于单靶点诱导，而忽视细胞器间信号交流网络的重要性，提出应通过整合细胞器间串话来增强焦亡的治疗潜力。文章的创新在于引入“细胞器-焦亡网络”这一框架，为癌症免疫治疗策略的转化提供新思路。但其局限在于主要基于现有文献综述，仍需更多实验验证支撑其推论。

---

## 13. t(11;14) 原发细胞遗传学异常及诊断时多种高危细胞遗传学异常的累积效应对原发性浆细胞白血病患者预后的影响。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41455693)
**期刊：** Blood cancer journal
**PMID：** 41455693
**DOI：** 10.1038/s41408-025-01442-2

### 第一部分 原文与翻译

**英文原标题：** Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究旨在探讨原发性浆细胞白血病患者中 t(11;14) 这一主要细胞遗传学异常的临床意义，以及诊断时多种高危遗传学异常的累积效应对患者预后的影响。虽然未提供摘要，但从标题推测，该工作可能基于细胞遗传学分层分析与生存结局数据，对个体化风险评估具有重要价值。研究结果有助于进一步理解 t(11;14) 与其他高危异常之间的交互作用，为精准治疗与风险导向策略提供新的证据。然而，若缺少详细方法与结果描述，研究结论的外推性仍需谨慎。

---

速递结束，祝您工作愉快！